NCT04425473View on ClinicalTrials.gov

Esketamine and Perioperative Depressive Symptoms

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

February 19, 2021

Primary Completion Date

June 23, 2024

Study Completion Date

November 27, 2024

Conditions
Depressive SymptomsEsketaminePerioperative ComplicationMajor Surgery
Interventions
DRUG

Esketamine

Esketamine will be administrated intravenously when suturing incision, with total dose of 0.2mg/kg and continuous infusion for 40 minutes.

DRUG

Normal saline

Equivalent amount of normal saline will be administrated intravenously suturing incision.

Trial Locations (1)

100070

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER

NCT04425473 - Esketamine and Perioperative Depressive Symptoms | Biotech Hunter | Biotech Hunter